Horizon Europe: Commission Reviews Research Funding as Mid-Term Results Show Strengths and Gaps

The European Commission's mid-term review of Horizon Europe research funding reveals strong output in some areas but persistent challenges in translating research to commercial applications.

Horizon Europe at the Midpoint: Record Applications, Mixed Commercialisation

The European Commission's review of Horizon Europe — the EU's €95.5 billion research and innovation programme running from 2021 to 2027 — presents a picture of genuine scientific achievement combined with persistent structural challenges in converting European research excellence into the commercial and economic success that programme funders and European competitiveness advocates want to see. The review, which draws on output data, economic impact assessments, and stakeholder consultations, is informing discussions about the design of the programme's successor, currently referred to as the 10th Framework Programme, which will run from 2028.

On the positive side, Horizon Europe has funded research that has contributed to multiple scientific breakthroughs, supported an extraordinary number of researcher careers through Marie Skłodowska-Curie Actions, built collaborative networks between European universities and research institutes that are genuinely world-class, and created the financial conditions for fundamental research in areas — quantum computing, advanced materials, life sciences, climate science — where European researchers are among the global leaders. The programme's open science requirements have also produced a substantial corpus of research outputs that are freely accessible worldwide, contributing to global scientific progress.

The challenge that the review identifies most consistently is the translation gap: the distance between excellent European research and successful European companies that commercialise it at scale. This gap exists for multiple reasons — a venture capital ecosystem that is thinner and more risk-averse than in the United States, cultural attitudes toward failure that punish researchers who leave academia for commercial ventures, regulatory environments that slow the path to market in some technology areas, and the difficulty of matching frontier research with the entrepreneurial talent needed to build world-scale companies.